X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DIVIS LABORATORIES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DIVIS LABORATORIES DISHMAN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 25.1 28.8 87.0% View Chart
P/BV x 3.3 5.0 67.0% View Chart
Dividend Yield % 0.7 1.0 67.0%  

Financials

 DISHMAN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES
Mar-17
DISHMAN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3741,222 30.6%   
Low Rs129784 16.4%   
Sales per share (Unadj.) Rs197.8153.1 129.2%  
Earnings per share (Unadj.) Rs21.239.9 53.1%  
Cash flow per share (Unadj.) Rs34.744.6 77.9%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.0 79.7%  
Book value per share (Unadj.) Rs179.9201.8 89.1%  
Shares outstanding (eoy) m80.69265.47 30.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.36.6 19.4%   
Avg P/E ratio x11.925.1 47.3%  
P/CF ratio (eoy) x7.222.5 32.2%  
Price / Book Value ratio x1.45.0 28.1%  
Dividend payout %9.425.0 37.7%   
Avg Mkt Cap Rs m20,306266,266 7.6%   
No. of employees `0000.89.7 8.5%   
Total wages/salary Rs m5,3554,687 114.2%   
Avg. sales/employee Rs Th19,252.74,175.0 461.1%   
Avg. wages/employee Rs Th6,459.5481.5 1,341.5%   
Avg. net profit/employee Rs Th2,064.11,089.3 189.5%   
INCOME DATA
Net Sales Rs m15,96140,643 39.3%  
Other income Rs m265749 35.4%   
Total revenues Rs m16,22641,392 39.2%   
Gross profit Rs m4,10314,460 28.4%  
Depreciation Rs m1,0911,233 88.4%   
Interest Rs m94423 4,178.8%   
Profit before tax Rs m2,33413,953 16.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6243,349 18.6%   
Profit after tax Rs m1,71110,604 16.1%  
Gross profit margin %25.735.6 72.3%  
Effective tax rate %26.724.0 111.3%   
Net profit margin %10.726.1 41.1%  
BALANCE SHEET DATA
Current assets Rs m11,01840,105 27.5%   
Current liabilities Rs m9,5176,595 144.3%   
Net working cap to sales %9.482.5 11.4%  
Current ratio x1.26.1 19.0%  
Inventory Days Days110119 93.2%  
Debtors Days Days3581 43.2%  
Net fixed assets Rs m16,30419,995 81.5%   
Share capital Rs m161531 30.4%   
"Free" reserves Rs m12,90753,043 24.3%   
Net worth Rs m14,51653,574 27.1%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80561,585 48.4%  
Interest coverage x3.5618.4 0.6%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.7 81.1%   
Return on assets %8.917.3 51.6%  
Return on equity %11.819.8 59.6%  
Return on capital %17.526.1 67.2%  
Exports to sales %24.80-   
Imports to sales %3.725.2 14.8%   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m59610,259 5.8%   
Fx inflow Rs m4,95235,384 14.0%   
Fx outflow Rs m69710,399 6.7%   
Net fx Rs m4,25524,985 17.0%   
CASH FLOW
From Operations Rs m2,78611,493 24.2%  
From Investments Rs m-1,529-11,372 13.4%  
From Financial Activity Rs m-941-93 1,010.8%  
Net Cashflow Rs m31628 1,114.1%  

Share Holding

Indian Promoters % 61.4 52.0 118.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.8 31.4%  
FIIs % 12.7 19.0 66.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.2 128.5%  
Shareholders   46,261 31,796 145.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  NOVARTIS  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS